



WGDA

Innovation, Evidence, and the Road Ahead



Prof. Mohamed Abdelghany

**Professor of Cardiology,
Cairo University
President of EgSC**



Prof. Hesham Salah El Din

**Professor of Cardiology,
Cairo University
President of WGDA**



8, 9 MAY 2026

At Helnan El Fayoum



WGD



Innovation, Evidence, and the Road Ahead

4:30-5:00

Registration



Opening Remarks Hesham Salah Aldin



01 Session

5:05 -5:20

The State of Art Lecture

Chairpersons: Alaa Etman, Hesham salah, Hazem Khamis, Magdy Alkadm.

5:05 -5:20

Small Vessels, Big Problems:
Perspectives on ANOCA, INOCA,
MINOCA

Kareem Said
(12 Min+3 Mins Discussion)

02 Session

5:20 -6:05

Precision Prevention: Heart, Liver, and Brain

Chairpersons: Abdallah Elagha, Amir Mostafa, Osama Amin, Tamer Mostafa.

5:20 -5:35

MASLD and Cardiovascular risk: A Cardiology
Perspective For 2026

Tamer Mostafa
(12 Min+3 Mins Discussion)

5:35 -5:50

Lipids and Dementia

Amir Mostafa
(12 Min+3 Mins Discussion)

5:50 -6:05

Using Imaging to Augment
Primary Prevention

Ahmed Asfour
(12 Min+3 Mins Discussion)

WEGDA

Innovation, Evidence, and the Road Ahead

03 Session

6:05 - 6:35

Novartis Symposium



Chairpersons: Ahmed Adel, Heba Eldeeb, Kareem Said, Mohamed Adel.

6:05 - 6:20

LEQVIO ; What is new

Hesham Salah
(12 Min+3 Mins Discussion)

6:20 - 6:35

Entresto on practice

Osama Amin
(12 Min+3 Mins Discussion)

04 Session

6:35 - 7:20

The Late-Breaking Clinical Trials

Chairpersons: Mohamed Abo Elezz, Hesham Salah, Mostafa Abdrabo, Mohamed Fayed.

6:35 - 6:50

VESALIUS-CV trial

Mohamed Fayed
(12 Min+3 Mins Discussion)

6:50 - 7:05

CORALreef trial

Mirna Mamdouh
(12 Min+3 Mins Discussion)

7:05 - 7:20

SURPASS-CVOT

Mostafa Abdrabo
(12 Min+3 Mins Discussion)

WORLD



Innovation, Evidence, and the Road Ahead

05 Session

7:20 - 7:50

Transatlantic Insights: Evolving Dyslipidemia Guidelines

Chairpersons: Alaa Etman, Ahmed Adel, Ahmed Asfour,
Tamer Mostafa.

7:20 - 7:35

The European Guidelines

Omar Eltahan

(12 Min+3 Mins Discussion)

7:35 - 7:50

The American Guidelines

Hadeer Gamal

(12 Min+3 Mins Discussion)

06 Session

7:50 - 8:20

Astra Zeneca Symposium

AstraZeneca 

Chairpersons: Abdallah Elagha, Amir Mostafa, Mohamed Kamis,
Osama Amin.

7:50 - 8:05

Hyperkalemia .. A life threatening
Risk in HF patients

Tamer Moustafa

(12 Min+3 Mins Discussion)

8:05 - 8:20

Heart Failure .. Real Patient Stories

Osama Amin

(12 Min+3 Mins Discussion)

WCGDA

Innovation, Evidence, and the Road Ahead

07 Session

8:20 - 9:05

Dyslipidemia in the Spotlight

Chairpersons: Heba Eldeeb, Mohamed Fayed, Magdy Alkadm, Mohamed Adel.

8:20 - 8:35

CETP Inhibition Revisited: From Biology To Therapeutic Target

Ahmed Adel
(12 Min+3 Mins Discussion)

8:35 - 8:50

Lp(a) Unveiled: The Next Chapter

Abdallah Elagha
(12 Min+3 Mins Discussion)

8:50 - 9:05

Turning The Paradigm: From Stepwise to "Start Early, and Hit Hard"

Mohamed Eltohfa
(12 Min+3 Mins Discussion)

08 Session

9:05 - 9:50

The Forgotten Particles and The Therapeutic Advances

Chairpersons: Ahmed Adel, Mohamed Abo Elezz, Mohamed Eltohfa, Mohamed Omar.

9:05 - 9:20

Novel Therapies for Remnant Cholesterol & TGs

Osama Saady
(12 Min+3 Mins Discussion)

9:20 - 9:35

Targeting Triglycerides in Diabetics: The Final Word

Mohamed Omar
(12 Min+3 Mins Discussion)

9:35 - 9:50

Effects of GLP-1 Receptor Agonists and SGL T2 Inhibitors on Lipid Metabolism

Mohamed Abo Elezz
(12 Min+3 Mins Discussion)

WGD



Innovation, Evidence, and the Road Ahead

09 Session

9:50 -10:10

Chairpersons: Hesham Salah, Mirna Mamdouh,
Hadeer Gamal, Mohamed Abo Elezz.

9:50 -10:10

EVA symposium

once weekly
mounjaro[®]
(tirzepatide) injection



Innovation, Evidence, and the Road Ahead

*Saturday
9 May, 2026*

The 2030 Dyslipidemia Guidelines:

10.00 am-12.00 pm

- 1. Trapped in Missing the LDL-C Targets**
- 2. Regionalized Risk Scoring – The Egyptian Model**
- 3. Rethinking Initial Therapy – From Sequential to Synergistic**
- 4. Empowering the Patient – From Misinformed to Engaged**